However, neither low RBM5 expression nor high KRAS expression were proved to be an independent factor associated with higher recurrence rate when corrected with age, gender, tumor size, lymphatic involvement, distant metastasis, cell differentiation, UICC stage and nerve and venous invasion. This evidence concerns the gene RBM5 and neoplasm.